Related Experiment Video

Updated: Aug 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting Aurora kinases in ovarian cancer

Siqing Fu1, Wei Hu, John J Kavanagh

  • 1Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230-1439, USA. siqingfu@mdanderson.org

Expert Opinion on Therapeutic Targets
|January 31, 2006
PubMed

Insights

Novel strategies targeting Aurora kinases are crucial for overcoming chemotherapy resistance in recurrent ovarian cancer. Developing Aurora kinase inhibitors as molecular agents may offer less toxic and more effective treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Recurrent epithelial ovarian cancer often develops resistance to conventional chemotherapy.
  • Aurora kinases are critical for cell division and are implicated in various cancers, including ovarian cancer.

Purpose of the Study:

  • To review the role of Aurora kinases and their inhibitors in epithelial ovarian cancer.
  • To explore strategies for reversing chemoresistance and developing novel therapeutic regimens.
  • To differentiate between cytotoxic and molecular therapeutic agents for ovarian cancer treatment.

Main Methods:

  • Literature review of Aurora kinases and their inhibitors in ovarian cancer.
  • Analysis of the mechanisms of action and toxicity profiles of therapeutic agents.
  • Comparison of cytotoxic and molecular therapeutic approaches.

Main Results:

  • Aurora kinases play a significant role in ovarian tumorigenesis and progression.
  • Aurora kinase inhibitors show potential as targeted therapies.
  • Differences in toxicity and dosage determination exist between cytotoxic and molecular agents.

Conclusions:

  • Targeting Aurora kinases presents a promising strategy to overcome chemoresistance in ovarian cancer.
  • Developing Aurora kinase inhibitors as molecular therapeutic agents could lead to improved efficacy and reduced toxicity.
  • Further research is needed to optimize Aurora kinase inhibitor-based regimens for ovarian cancer treatment.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...